BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Muratori P, Muratori L, Gershwin ME, Czaja AJ, Pappas G, MacCariello S, Granito A, Cassani F, Loria P, Lenzi M. ‘True’ antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both? Clin Exp Immunol. 2004;135:154-158. [PMID: 14678277 DOI: 10.1111/j.1365-2249.2004.02332.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Villalta D, Seaman A, Tiongson M, Warren C, Bentow C, Bizzaro N, Alessio MG, Porcelli B, Norman GL, Mahler M. Evaluation of a novel extended automated particle-based multi-analyte assay for the detection of autoantibodies in the diagnosis of primary biliary cholangitis. Clin Chem Lab Med 2020;58:1499-507. [PMID: 32286240 DOI: 10.1515/cclm-2020-0122] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
2 Selmi C, Bowlus CL, Gershwin ME, Coppel RL. Primary biliary cirrhosis. Lancet. 2011;377:1600-1609. [PMID: 21529926 DOI: 10.1016/s0140-6736(10)61965-4] [Cited by in Crossref: 193] [Cited by in F6Publishing: 85] [Article Influence: 17.5] [Reference Citation Analysis]
3 Dellavance A, Cançado EL, Abrantes-Lemos CP, Harriz M, Marvulle V, Andrade LE. Humoral autoimmune response heterogeneity in the spectrum of primary biliary cirrhosis. Hepatol Int 2013;7:775-84. [PMID: 23853697 DOI: 10.1007/s12072-012-9413-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
4 Muratori P, Granito A, Pappas G, Pendino GM, Quarneti C, Cicola R, Menichella R, Ferri S, Cassani F, Bianchi FB, Lenzi M, Muratori L. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol 2009;104:1420-5. [PMID: 19491855 DOI: 10.1038/ajg.2009.126] [Cited by in Crossref: 73] [Cited by in F6Publishing: 55] [Article Influence: 5.6] [Reference Citation Analysis]
5 Fallatah HI, Akbar HO. Autoimmune liver disease - are there spectra that we do not know? Comp Hepatol. 2011;10:9. [PMID: 21910861 DOI: 10.1186/1476-5926-10-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
6 Zachou K, Muratori P, Koukoulis GK, Granito A, Gatselis N, Fabbri A, Dalekos GN, Muratori L. Review article: autoimmune hepatitis -- current management and challenges. Aliment Pharmacol Ther. 2013;38:887-913. [PMID: 24010812 DOI: 10.1111/apt.12470] [Cited by in Crossref: 99] [Cited by in F6Publishing: 88] [Article Influence: 11.0] [Reference Citation Analysis]
7 Rigopoulou EI, Dalekos GN. Molecular diagnostics of primary biliary cirrhosis. Expert Opin Med Diagn. 2008;2:621-634. [PMID: 23495774 DOI: 10.1517/17530059.2.6.621] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
8 Montano-Loza AJ, Carpenter HA, Czaja AJ. Frequency, behavior, and prognostic implications of antimitochondrial antibodies in type 1 autoimmune hepatitis. J Clin Gastroenterol. 2008;42:1047-1053. [PMID: 18719506 DOI: 10.1097/mcg.0b013e3181587d18] [Cited by in Crossref: 40] [Cited by in F6Publishing: 14] [Article Influence: 2.9] [Reference Citation Analysis]
9 Sebode M, Weiler-Normann C, Liwinski T, Schramm C. Autoantibodies in Autoimmune Liver Disease-Clinical and Diagnostic Relevance. Front Immunol. 2018;9:609. [PMID: 29636752 DOI: 10.3389/fimmu.2018.00609] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 8.8] [Reference Citation Analysis]
10 Chantran Y, Ballot É, Johanet C. Autoantibodies in primary biliary cirrhosis: Antimitochondrial autoantibodies. Clinics and Research in Hepatology and Gastroenterology 2013;37:431-3. [DOI: 10.1016/j.clinre.2013.05.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
11 Chascsa DM, Lindor KD. Antimitochondrial Antibody-Negative Primary Biliary Cholangitis: Is It Really the Same Disease? Clin Liver Dis. 2018;22:589-601. [PMID: 30259855 DOI: 10.1016/j.cld.2018.03.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Cançado GGL, Braga MH, Ferraz MLG, Villela-Nogueira CA, Terrabuio DRB, Cançado ELR, Nardelli MJ, Faria LC, de Faria Gomes NM, Oliveira EMG, Rotman V, Oliveira MB, da Cunha SMCF, Cunha-Silva M, Mendes LSC, Ivantes CAP, Codes L, de Almeida E Borges VF, de Lima Pace FH, Pessoa MG, Signorelli IV, Coral GP, Bittencourt PL, Levy C, Couto CA; Members of the Brazilian Cholestasis Study Group Consortium. Anti-mitochondrial Antibody-Negative Primary Biliary Cholangitis Is Part of the Same Spectrum of Classical Primary Biliary Cholangitis. Dig Dis Sci 2021. [PMID: 34181166 DOI: 10.1007/s10620-021-07122-y] [Reference Citation Analysis]
13 Lee DH, Huh SJ, Yoon HH, Lee SW, Kim KH, Kim SH. Clinical significance of anti-mitochondrial antibodies in a patient with chronic graft-versus-host disease following hematopoietic stem cell transplantation. Korean J Hematol 2011;46:200-2. [PMID: 22065977 DOI: 10.5045/kjh.2011.46.3.200] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
14 Volta U, Caio G, Tovoli F, De Giorgio R. Gut-liver axis: an immune link between celiac disease and primary biliary cirrhosis. Expert Rev Gastroenterol Hepatol 2013;7:253-61. [PMID: 23445234 DOI: 10.1586/egh.13.5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
15 Ronca V, Chen QB, Lygoura V, Ben‐mustapha I, Shums Z, Trifa M, Carbone M, Mancuso C, Milani C, Bernuzzi F, Ma X, Agrebi N, Norman GL, Chang C, Gershwin ME, Barbouche M, Invernizzi P. Autoantibodies in patients with interleukin 12 receptor beta 1 deficiency. J Dig Dis 2019;20:363-70. [DOI: 10.1111/1751-2980.12790] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Czaja AJ. The overlap syndromes of autoimmune hepatitis. Dig Dis Sci. 2013;58:326-343. [PMID: 22918690 DOI: 10.1007/s10620-012-2367-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 23] [Article Influence: 0.3] [Reference Citation Analysis]
17 Vergani D, Alvarez F, Bianchi FB, Cançado EL, Mackay IR, Manns MP, Nishioka M, Penner E. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol. 2004;41:677-683. [PMID: 15464251 DOI: 10.1016/j.jhep.2004.08.002] [Cited by in Crossref: 269] [Cited by in F6Publishing: 218] [Article Influence: 15.8] [Reference Citation Analysis]
18 Brunt EM, Neuschwander-tetri BA, Burt AD. Fatty liver disease. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 293-359. [DOI: 10.1016/b978-0-7020-3398-8.00006-4] [Cited by in Crossref: 9] [Article Influence: 0.9] [Reference Citation Analysis]
19 Miyachi K, Hosaka H, Nakamura N, Miyakawa H, Mimori T, Shibata M, Matsushima S, Chinoh H, Horigome T, Hankins RW. Anti-p97/VCP antibodies: an autoantibody marker for a subset of primary biliary cirrhosis patients with milder disease? Scand J Immunol. 2006;63:376-382. [PMID: 16640662 DOI: 10.1111/j.1365-3083.2006.01747.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
20 Muratori L, Granito A, Muratori P, Pappas G, Bianchi FB. Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis: diagnostic and prognostic value. Clin Liver Dis. 2008;12:261-276; vii. [PMID: 18456179 DOI: 10.1016/j.cld.2008.02.009] [Cited by in Crossref: 49] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
21 Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, Zein CO, Brunt EM, Kleiner DE, McCullough AJ, Sanyal AJ, Diehl AM, Lavine JE, Chalasani N, Kowdley KV; NASH Clinical Research Network. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010;52:913-24. [PMID: 20648476 DOI: 10.1002/hep.23784] [Cited by in Crossref: 290] [Cited by in F6Publishing: 276] [Article Influence: 24.2] [Reference Citation Analysis]
22 Norman GL, Reig A, Viñas O, Mahler M, Wunsch E, Milkiewicz P, Swain MG, Mason A, Stinton LM, Aparicio MB, Aldegunde MJ, Fritzler MJ, Parés A. The Prevalence of Anti-Hexokinase-1 and Anti-Kelch-Like 12 Peptide Antibodies in Patients With Primary Biliary Cholangitis Is Similar in Europe and North America: A Large International, Multi-Center Study. Front Immunol 2019;10:662. [PMID: 31001269 DOI: 10.3389/fimmu.2019.00662] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
23 Gatselis NK, Zachou K, Norman GL, Gabeta S, Papamichalis P, Koukoulis GK, Dalekos GN. Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease. Autoimmunity. 2013;46:471-479. [PMID: 23777462 DOI: 10.3109/08916934.2013.801461] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
24 Czaja AJ. Review article: the management of autoimmune hepatitis beyond consensus guidelines. Aliment Pharmacol Ther 2013;38:343-64. [DOI: 10.1111/apt.12381] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
25 Li XJ, Yang JH. Clinical and pathological features of primary biliary cirrhotic patients with negative anti-mitochondria antibody M2 subtype. Shijie Huaren Xiaohua Zazhi 2009; 17(16): 1676-1679 [DOI: 10.11569/wcjd.v17.i16.1676] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Czaja AJ. Autoantibodies as prognostic markers in autoimmune liver disease. Dig Dis Sci. 2010;55:2144-2161. [PMID: 20464491 DOI: 10.1007/s10620-010-1268-4] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 4.1] [Reference Citation Analysis]
27 Baldo DC, Dellavance A, Ferraz MLG, Andrade LEC. Evolving liver inflammation in biochemically normal individuals with anti-mitochondria antibodies. Auto Immun Highlights 2019;10:10. [PMID: 32257066 DOI: 10.1186/s13317-019-0120-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Cavazzana I, Ceribelli A, Taraborelli M, Fredi M, Norman G, Tincani A, Satoh M, Franceschini F. Primary Biliary Cirrhosis-related Autoantibodies in a Large Cohort of Italian Patients with Systemic Sclerosis. J Rheumatol 2011;38:2180-5. [DOI: 10.3899/jrheum.110167] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
29 Liaskos C, Bogdanos DP, Rigopoulou EI, Dalekos GN. Development of antimitochondrial antibodies in patients with autoimmune hepatitis: art of facts or an artifact? J Gastroenterol Hepatol. 2007;22:454-455. [PMID: 17295788 DOI: 10.1111/j.1440-1746.2006.04751.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
30 Granito A, Yang W, Muratori L, Lim MJ, Nakajima A, Ferri S, Pappas G, Quarneti C, Bianchi FB, Bloch DB, Muratori P. PML Nuclear Body Component Sp140 Is a Novel Autoantigen in Primary Biliary Cirrhosis. American Journal of Gastroenterology 2010;105:125-31. [DOI: 10.1038/ajg.2009.596] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 4.3] [Reference Citation Analysis]
31 Czaja AJ. Autoimmune liver disease: . Current Opinion in Gastroenterology 2005;21:293-9. [DOI: 10.1097/01.mog.0000155360.43763.41] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
32 Czaja AJ. Cholestatic phenotypes of autoimmune hepatitis. Clin Gastroenterol Hepatol 2014;12:1430-8. [PMID: 24013108 DOI: 10.1016/j.cgh.2013.08.039] [Cited by in Crossref: 39] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
33 Hu CJ, Zhang FC, Li YZ, Zhang X. Primary biliary cirrhosis: What do autoantibodies tell us? World J Gastroenterol 2010; 16(29): 3616-3629 [PMID: 20677333 DOI: 10.3748/wjg.v16.i29.3616] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
34 Gatselis NK, Zachou K, Koukoulis GK, Dalekos GN. Autoimmune hepatitis, one disease with many faces: Etiopathogenetic, clinico-laboratory and histological characteristics. World J Gastroenterol 2015; 21(1): 60-83 [PMID: 25574080 DOI: 10.3748/wjg.v21.i1.60] [Cited by in CrossRef: 73] [Cited by in F6Publishing: 66] [Article Influence: 10.4] [Reference Citation Analysis]
35 Muratori P, Efe C, Muratori L, Ozaslan E, Schiano T, Yoshida EM, Heurgué-berlot A, Lalanne C, Lenzi M, Wahlin S. Clinical implications of antimitochondrial antibody seropositivity in autoimmune hepatitis: a multicentre study. European Journal of Gastroenterology & Hepatology 2017;29:777-80. [DOI: 10.1097/meg.0000000000000870] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
36 Czaja AJ. Diagnosis and management of the overlap syndromes of autoimmune hepatitis. Can J Gastroenterol. 2013;27:417-423. [PMID: 23862175 DOI: 10.1155/2013/198070] [Cited by in Crossref: 42] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
37 Czaja AJ, Bayraktar Y. Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment. World J Gastroenterol 2009; 15(19): 2314-2328 [PMID: 19452572 DOI: 10.3748/wjg.15.2314] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
38 Boberg KM, Chapman RW, Hirschfield GM, Lohse AW, Manns MP, Schrumpf E; International Autoimmune Hepatitis Group. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol. 2011;54:374-385. [PMID: 21067838 DOI: 10.1016/j.jhep.2010.09.002] [Cited by in Crossref: 310] [Cited by in F6Publishing: 246] [Article Influence: 25.8] [Reference Citation Analysis]
39 Achenza MI, Meda F, Brunetta E, Selmi C. Serum autoantibodies for the diagnosis and management of autoimmune liver diseases. Expert Rev Gastroenterol Hepatol. 2012;6:717-729. [PMID: 23237257 DOI: 10.1586/egh.12.58] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
40 Gatselis NK, Dalekos GN. Molecular diagnostic testing for primary biliary cholangitis. Expert Review of Molecular Diagnostics 2016;16:1001-10. [DOI: 10.1080/14737159.2016.1217159] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
41 Liu H, Norman GL, Shums Z, Worman HJ, Krawitt EL, Bizzaro N, Vergani D, Bogdanos DP, Dalekos GN, Milkiewicz P. PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J Autoimmun. 2010;35:436-442. [PMID: 20932720 DOI: 10.1016/j.jaut.2010.09.005] [Cited by in Crossref: 93] [Cited by in F6Publishing: 85] [Article Influence: 7.8] [Reference Citation Analysis]
42 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2005; 13(12): 1478-1481 [DOI: 10.11569/wcjd.v13.i12.1478] [Reference Citation Analysis]
43 Bargou I, Mankaï A, Jamaa A, Ben Jazia I, Skandrani K, Sfar H, Baccouche A, Ajmi S, Letaief A, Fabien N, Jeddi M, Ghedira I. Detection of M2 antimitochondrial antibodies by dot blot assay is more specific than by enzyme linked immunosorbent assay. Pathologie Biologie 2008;56:10-4. [DOI: 10.1016/j.patbio.2007.05.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
44 Gabeta S, Norman GL, Liaskos C, Papamichalis PA, Zografos T, Garagounis A, Rigopoulou EI, Dalekos GN. Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis. J Clin Immunol 2007;27:378-87. [PMID: 17514501 DOI: 10.1007/s10875-007-9092-0] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 2.8] [Reference Citation Analysis]
45 Weetman AP. Non-thyroid autoantibodies in autoimmune thyroid disease. Best Pract Res Clin Endocrinol Metab. 2005;19:17-32. [PMID: 15826920 DOI: 10.1016/j.beem.2004.11.004] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 2.8] [Reference Citation Analysis]
46 Marzorati S, Invernizzi P, Lleo A. Making Sense of Autoantibodies in Cholestatic Liver Diseases. Clinics in Liver Disease 2016;20:33-46. [DOI: 10.1016/j.cld.2015.08.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
47 Eugenia Rinella M. Primary biliary cirrhosis. Annals of Hepatology 2006;5:198-200. [DOI: 10.1016/s1665-2681(19)32010-1] [Reference Citation Analysis]
48 Quarneti C, Muratori P, Lalanne C, Fabbri A, Menichella R, Granito A, Masi C, Lenzi M, Cassani F, Pappas G. Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis. Liver Int. 2015;35:636-641. [PMID: 24698666 DOI: 10.1111/liv.12560] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
49 Juliusson G, Imam M, Björnsson ES, Talwalkar JA, Lindor KD. Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis. Scand J Gastroenterol. 2016;51:745-752. [PMID: 26776319 DOI: 10.3109/00365521.2015.1132337] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
50 Czaja AJ, Carpenter HA. Autoimmune Hepatitis Overlap Syndromes and Liver Pathology. Gastroenterology Clinics of North America 2017;46:345-64. [DOI: 10.1016/j.gtc.2017.01.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
51 Granito A, Muratori P, Muratori L, Pappas G, Cassani F, Worthington J, Guidi M, Ferri S, DE Molo C, Lenzi M. Antinuclear antibodies giving the ‘multiple nuclear dots’ or the ‘rim-like/membranous’ patterns: diagnostic accuracy for primary biliary cirrhosis. Aliment Pharmacol Ther. 2006;24:1575-1583. [PMID: 17206945 DOI: 10.1111/j.1365-2036.2006.03172.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
52 Barbouche MR, Chen Q, Carbone M, Ben-Mustapha I, Shums Z, Trifa M, Malinverno F, Bernuzzi F, Zhang H, Agrebi N, Norman GL, Chang C, Gershwin ME, Invernizzi P. Comprehensive review of autoantibodies in patients with hyper-IgM syndrome. Cell Mol Immunol 2018;15:610-7. [PMID: 29400703 DOI: 10.1038/cmi.2017.140] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Terjung B, Spengler U. Role of auto-antibodies for the diagnosis of chronic cholestatic liver diseases. Clin Rev Allergy Immunol. 2005;28:115-133. [PMID: 15879618 DOI: 10.1385/criai:28:2:115] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
54 Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, Vierling JM, Alsawas M, Murad MH, Czaja AJ. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 2020;72:671-722. [PMID: 31863477 DOI: 10.1002/hep.31065] [Cited by in Crossref: 104] [Cited by in F6Publishing: 94] [Article Influence: 52.0] [Reference Citation Analysis]
55 Bogdanos DP, Komorowski L. Disease-specific autoantibodies in primary biliary cirrhosis. Clin Chim Acta. 2011;412:502-512. [PMID: 21185272 DOI: 10.1016/j.cca.2010.12.019] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 5.6] [Reference Citation Analysis]
56 Hu C, Deng C, Song G, Zhang W, Zhang S, Li X, Li P, Zhang F, Li Y. Prevalence of autoimmune liver disease related autoantibodies in Chinese patients with primary biliary cirrhosis. Dig Dis Sci. 2011;56:3357-3363. [PMID: 21660486 DOI: 10.1007/s10620-011-1756-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
57 Zhou T, Kundu D, Robles-Linares J, Meadows V, Sato K, Baiocchi L, Ekser B, Glaser S, Alpini G, Francis H, Kennedy L. Feedback Signaling between Cholangiopathies, Ductular Reaction, and Non-Alcoholic Fatty Liver Disease. Cells 2021;10:2072. [PMID: 34440841 DOI: 10.3390/cells10082072] [Reference Citation Analysis]
58 Czaja AJ. Autoantibodies in autoimmune liver disease. Adv Clin Chem. 2005;40:127-164. [PMID: 16355922 DOI: 10.1016/s0065-2423(05)40004-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
59 Seike T, Komura T, Shimizu Y, Omura H, Kumai T, Kagaya T, Ohta H, Kawashima A, Harada K, Kaneko S, Unoura M. A Young Man with Non-alcoholic Steatohepatitis and Serum Anti-mitochondrial Antibody Positivity. Intern Med 2018;57:3093-7. [PMID: 29877264 DOI: 10.2169/internalmedicine.0405-17] [Reference Citation Analysis]
60 Morisco F, Pagliaro L, Caporaso N, Bianco E, Sagliocca L, Fargion S, Smedile A, Salvagnini M, Mele A. Consensus recommendations for managing asymptomatic persistent non-virus non-alcohol related elevation of aminotransferase levels: suggestions for diagnostic procedures and monitoring. Dig Liver Dis. 2008;40:585-598. [PMID: 18395501 DOI: 10.1016/j.dld.2008.02.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
61 Milkiewicz P, Buwaneswaran H, Coltescu C, Shums Z, Norman GL, Heathcote EJ. Value of autoantibody analysis in the differential diagnosis of chronic cholestatic liver disease. Clin Gastroenterol Hepatol. 2009;7:1355-1360. [PMID: 19631286 DOI: 10.1016/j.cgh.2009.07.012] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
62 Smyk DS, Rigopoulou EI, Muratori L, Burroughs AK, Bogdanos DP. Smoking as a risk factor for autoimmune liver disease: what we can learn from primary biliary cirrhosis. Annals of Hepatology 2012;11:7-14. [DOI: 10.1016/s1665-2681(19)31481-4] [Cited by in Crossref: 25] [Article Influence: 2.5] [Reference Citation Analysis]
63 He XS, Ansari AA, Ridgway WM, Coppel RL, Gershwin ME. New insights to the immunopathology and autoimmune responses in primary biliary cirrhosis. Cell Immunol. 2006;239:1-13. [PMID: 16765923 DOI: 10.1016/j.cellimm.2006.04.006] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 3.2] [Reference Citation Analysis]
64 Norman GL, Bialek A, Encabo S, Butkiewicz B, Wiechowska-Kozlowska A, Brzosko M, Shums Z, Milkiewicz P. Is prevalence of PBC underestimated in patients with systemic sclerosis? Dig Liver Dis. 2009;41:762-764. [PMID: 19357001 DOI: 10.1016/j.dld.2009.01.014] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
65 Muratori P, Granito A, Pappas G, Muratori L, Lenzi M, Bianchi FB. Autoimmune liver disease 2007. Mol Aspects Med 2008;29:96-102. [PMID: 18067956 DOI: 10.1016/j.mam.2007.09.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]